Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PAVmed (PAVM) Other Non-Current Liabilities (2023 - 2025)

Historic Other Non-Current Liabilities for PAVmed (PAVM) over the last 3 years, with Q3 2025 value amounting to $6.9 million.

  • PAVmed's Other Non-Current Liabilities changed N/A to $6.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.9 million, marking a year-over-year change of. This contributed to the annual value of $29.1 million for FY2024, which is 3416.29% down from last year.
  • As of Q3 2025, PAVmed's Other Non-Current Liabilities stood at $6.9 million.
  • In the past 5 years, PAVmed's Other Non-Current Liabilities registered a high of $44.2 million during Q4 2023, and its lowest value of $260000.0 during Q2 2023.
  • For the 3-year period, PAVmed's Other Non-Current Liabilities averaged around $13.5 million, with its median value being $6.8 million (2025).
  • Data for PAVmed's Other Non-Current Liabilities shows a peak YoY increase of 3416.29% (in 2024) and a maximum YoY decrease of 3416.29% (in 2024) over the last 5 years.
  • Over the past 3 years, PAVmed's Other Non-Current Liabilities (Quarter) stood at $44.2 million in 2023, then tumbled by 34.16% to $29.1 million in 2024, then crashed by 76.29% to $6.9 million in 2025.
  • Its Other Non-Current Liabilities stands at $6.9 million for Q3 2025, versus $6.8 million for Q2 2025 and $6.6 million for Q1 2025.